Article Text

Download PDFPDF

882 Timing and sequencing of AR-specific vaccination combined with androgen deprivation therapy affect anti-tumor responses in murine prostate cancer models
  1. Anusha Muralidhar and
  2. Douglas McNeel
  1. University of Wisconsin-Madison, Madison, WI, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Androgen deprivation therapy (ADT) is the cornerstone treatment for recurrent and metastatic prostate cancer. ADT has several immunomodulatory effects including T cell infiltration into the prostate and enhancing antigen processing and/or presentation.1–3 Previous studies have demonstrated that immunizing tumor-bearing mice with a DNA vaccine encoding the androgen receptor significantly slowed tumor growth and prolonged survival.4–6 Furthermore, combining ADT with vaccination further augmented the anti-tumor response compared to AR-targeted vaccination alone, and this was greatest if DNA vaccination was given prior to ADT.7–10 We observed a transient increase in T cell infiltration post ADT and a significant accumulation of MDSCs in the tumor microenvironment. In this study, we characterized CD8+ T cells for antigen specificity following vaccination and determined if depletion of MDSCs could increase anti-tumor efficacy.

Methods 6-week-old male FVB mice were implanted subcutaneously with Myc-CaP tumor cells. DNA vaccination consisted of the pTVG4 vector alone (control) or the DNA vector encoding the AR ligand binding domain (pTVG-AR) started either one day after tumor implantation, or one day following ADT. The sequence of administration was evaluated for effect on tumor growth, and groups of mice were euthanized at different time points to characterize the tumor-infiltrating immune populations by flow cytometry. Further, CD8+ T cells were isolated from tumors and tested for AR specificity by IFNγ ELISPOT using an AR-specific dominant FVB epitope, AR-25. In a similar study, tumor-bearing mice were treated with control or clodronate liposomes twice a week post ADT and infiltrating immune populations were characterized.

Results Vaccination prior to ADT rather than after ADT significantly improved anti- tumor responses and flow cytometry analysis of tumor immune infiltrates revealed a higher infiltration of CD4+ and CD8+ T cells in this group. Infiltrating CD8+ T cells were found to be AR-specific by IFNγ ELISPOT. Depletion of these cells resulted in significantly worse survival. MDSCs were significantly increased in tumors following ADT in all combination groups and depletion of these cells using clodronate liposomes resulted in improved anti-tumor response and overall survival.

Conclusions Vaccination prior to ADT rather than after ADT significantly improved anti-tumor responses and this affected the infiltrating immune populations. Depletion of MDSCs using clodronate liposomes significantly improved anti-tumor responses and increased infiltration of CD4+ and CD8+ T cells into prostate tumors. Since ADT causes accumulation of MDSCs within the tumors, current studies are investigating the intermittent use of ADT as an alternative to continuous treatment when combined with anti-tumor vaccination.


  1. Vitkin N, Nersesian S, Siemens DR, Koti M. The tumor immune contexture of prostate cancer. Immunol. 2019;10:603. doi: 10.3389/fimmu.2019.00603.

  2. Prokhnevska N, Emerson DA, Kissick HT, Redmond WL. Immunological complexity of the prostate cancer microenvironment influences the response to immunotherapy. Exp. Med. Biol. 2019;1210:121–147

  3. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004;173(10):6098–108.

  4. McNeel DG, Becker JT, Johnson LE, Olson BM. DNA vaccines for prostate cancer. Cancer Ther. Rev. 2012;8:254–263.

  5. Colluru VT, Johnson LE, Olson BM, McNeel DG. Preclinical and clinical development of DNA vaccines for prostate cancer. Urologic oncology. 2016;34(4):193–204. doi: 10.1016/j.urolonc.2013.09.014

  6. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage d0 prostate cancer. Clin. Oncol. 2009;27:4047–4054. doi: 10.1200/JCO.2008.19.9968

  7. Olson BM, Gamat M, Seliski J, Sawicki T, Jeffery J, Ellis L, Drake CG, Weichert J, McNeel DG. Prostate cancer cells express more androgen receptor (ar) following androgen deprivation, improving recognition by ar-specific t cells. Cancer Immunol. Res. 2017;5:1074–1085. doi: 10.1158/2326-6066.CIR-16-0390.

  8. Johnson LE, Olson BM, McNeel DG. Pretreatment antigen-specific immunity and regulation-association with subsequent immune response to anti-tumor DNA vaccination. Immunother. Cancer. 2017;5:56. doi: 10.1186/s40425-017-0260-3.

  9. Morse MD, McNeel DG. T cells localized to the androgen-deprived prostate are th1 and th17 biased. 2012;72:1239–1247. doi: 10.1002/pros.22476.

  10. Alva A, Hussain M. Intermittent androgen deprivation therapy in advanced prostate cancer. Curent Treatment Options in Oncology 2014;15:127–136.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.